Head office

3F #307, 288, Digital-ro, Guro-gu,

Seoul, 08390, Republic of Korea

R&D center

3F #304~307, #314, 288, Digital-ro,

Guro-gu, Seoul, 08390, Republic of Korea

Email

business@ngenebio.com

Tel

02-867-9798

Fax

02-866-9784

NGeneBio

CEO’s Message

Greetings,
I’m Choi Dae-chul, the CEO of NGeneBio.

The current landscape of the healthcare industry can be summed up as the “4P medicine”: implementation of “predictive” and “preventive” measures before disease onset, “participatory” healthcare measures to lead a healthy life, and “personalized” treatment for patients with diseases. We are also ushering in the era of precision medicine with the convergence of technologies such as genome/bio informatics analysis, artificial intelligence (AI), and big data.

In line with these trends, we have commercialized a precision diagnostics platform by combining biotechnology (BT) and information technology (IT) and are offering precision diagnostics to assist patients suffering from diseases and high medical expenses in finding optimal treatment. We are also dedicated to practicing 4P medicine by offering services that provide personalized diet, exercise regimens and information, and disease prevention based on genetic analysis.

At NGeneBio, we apply stringent quality controls to our diagnostic products and test services. We have also acquired a number of certifications such as ISO 9001 (Quality management), ISO 13485 (Quality management for medical devices), and ISO/IEC 27001:2013 (Information security management) in order to internalize “quality management” throughout the company and continuously improve the quality of our products and services.

We are making ceaseless efforts to develop innovative precision diagnostic technology based on the convergence of BT and IT. As a result, we have achieved tangible results in the areas of companion diagnostics related to anticancer drugs, liquid biopsy necessary for prognosis and prediction of diseases, and diagnosis of infectious diseases such as tuberculosis and viral diseases.

On behalf of the executives and employees of NGeneBio, I’d like to express our gratitude to our shareholders and customers and vow to do our best to become a company that promotes health and happiness for everyone with innovative products and services.

 

Thank you.

CEO Choi Dae-chul